Cogent Biosciences, Inc.
Income Statement
| Line Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Revenue | $7.9M | $22.5M | $9.7M | $8.4M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $25.7M | $43.7M | $38.3M | $29.8M |
| SG&A Expense | $17.4M | $11.0M | $7.5M | $4.7M |
| Operating Income | $-82.2M | $-32.2M | $-36.0M | $-26.2M |
| Operating Margin | -1,044.3% | -143.0% | -369.9% | -312.8% |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | — | — | — | — |
| Net Income | $-74.8M | $-31.8M | $-34.5M | $-25.5M |
| Net Margin | -950.4% | -141.5% | -354.8% | -304.9% |
| EPS (Basic) | $-16.17 | $-4.18 | $-1.39 | $-2.51 |
| EPS (Diluted) | $-16.17 | $-4.18 | $-1.39 | $-2.51 |
| Shares Outstanding (Basic) | 32.3M | 7.7M | 30.1M | 10.2M |
| Shares Outstanding (Diluted) | 32.3M | 7.7M | 30.1M | 10.2M |
| Dividends Per Share | — | — | — | — |